Eledon Pharmaceuticals, Inc. (ELDN) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Irvine, CA, United States. The current CEO is David-Alexandre C. Gros.
ELDN has IPO date of 2014-09-17, 31 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $191.84M.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
